Welcome to our dedicated page for Castle Biosciences SEC filings (Ticker: CSTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Castle Biosciences, Inc. (CSTL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed issuer. Castle Biosciences files reports with the U.S. Securities and Exchange Commission that cover its financial performance, governance changes, risk factors and material events related to its molecular diagnostics business in dermatologic and gastroenterological disease.
Investors can review current reports on Form 8-K, where Castle discloses items such as quarterly financial results, updated revenue guidance, the release of investor presentations and amendments to its bylaws. For example, 8-K filings describe when the company announces earnings for periods such as the quarter ended September 30, 2025, or when its board adopts amended and restated bylaws addressing stockholder meetings, director nominations, voting standards and indemnification provisions.
Alongside 8-Ks, users can access annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the SEC feed). These filings typically contain audited or reviewed financial statements, management’s discussion and analysis of results, details on Castle’s test portfolio, information about markets served and disclosures about risks associated with its diagnostics operations.
For those monitoring governance and capital structure, the SEC filings also identify Castle Biosciences’ state of incorporation (Delaware), the class of securities registered (common stock, $0.001 par value per share) and its listing on The Nasdaq Global Market under the symbol CSTL.
Stock Titan enhances this raw filing data with AI-powered summaries that explain key points in accessible language. Users can quickly see the main themes of a lengthy 10-K or 10-Q, identify notable changes in guidance or governance reported in 8-Ks, and navigate directly to sections that matter most for understanding Castle Biosciences’ molecular diagnostics business.
Castle Biosciences Chief Financial Officer Frank Stokes sold 6,001 shares of common stock on March 5, 2026 in an open-market transaction at a weighted-average price of $27.98 per share. The sale was made under a prearranged Rule 10b5-1 trading plan adopted on November 13, 2025.
The transaction was executed in multiple trades at prices ranging from $27.51 to $28.41 per share, with the reported price reflecting the weighted average. After this planned sale, Stokes continues to directly own 60,085 shares of Castle Biosciences common stock.
Castle Biosciences director Cole G Bradley reported option exercises and stock sales. On March 5, 2026, Bradley exercised stock options for 4,748 shares and received an equal number of common shares. He then sold a total of 7,403 common shares in open-market transactions and held 19,309 shares directly afterward.
Castle Biosciences Chief Commercial Officer Juvenal Tobin W reported several equity compensation transactions in early March 2026. On March 3, he received a grant of 48,367 Restricted Stock Units (RSUs), each representing one share of common stock, which will vest in four equal annual installments beginning March 3, 2027.
On March 4, previously granted RSUs were exercised into common stock, and 10,399 shares and 3,716 shares of common stock were withheld to cover tax obligations in connection with vested performance or restricted stock units. After these transactions, his directly held common stock and RSU positions increased overall.
Castle Biosciences Chief Operating Officer Kristen M. Oelschlager reported several equity compensation transactions involving restricted stock units (RSUs) and common stock. On March 3, 2026, she received a grant of 48,367 RSUs, which vest in four equal annual installments beginning on March 3, 2027.
On March 4, 2026, she exercised or converted RSUs covering 13,811 and 11,960 RSUs at a price of $0.00 per unit, resulting in 25,771 shares of common stock acquired through derivative exercises. The filing also reports dispositions of 6,792 and 2,427 shares of common stock at $28.17 and $27.57 per share, respectively, to satisfy tax withholding obligations in connection with vested performance stock units.
Following these transactions, she holds common stock directly and also has an indirect holding of 97,251 shares of common stock through The Fritz Shorter Trust, of which she and her spouse are trustees and beneficiaries. Each RSU represents the right to receive one share of Castle Biosciences common stock.
Castle Biosciences president and CEO Derek J. Maetzold reported several equity compensation transactions in company stock. On March 3, 2026, he received a grant of 102,597 Restricted Stock Units (RSUs), which, according to a footnote, vest in four equal annual installments beginning on March 3, 2027.
On March 4, 2026, RSUs previously granted were converted into a total of 59,097 shares of common stock through derivative exercises. On March 3 and March 4, 2026, a combined 36,974 shares of common stock were disposed of at prices of $27.57 and $28.17 per share to satisfy tax withholding obligations.
The filing also lists indirect holdings of common stock in multiple trusts, including The Maetzold Descendants 2020 Trust and several Maetzold remainder and grantor retained annuity trusts, where Maetzold or his spouse serves as trustee and certain family members are beneficiaries.
Castle Biosciences Chief Financial Officer Frank Stokes reported a mix of stock awards, option exercises, sales, and tax-related share withholdings. On March 3, 2026, he was granted 48,367 Restricted Stock Units (RSUs), each representing one share of common stock, vesting in four equal annual installments beginning March 3, 2027.
That same day, he sold 5,300 and 1,700 shares of common stock at weighted-average prices of $27.32 and $27.81 in open-market transactions under a Rule 10b5‑1 trading plan. He also disposed of 3,611 shares at $27.57 to cover tax withholding on previously vested performance stock units.
On March 4, 2026, Stokes exercised derivative awards, converting 12,186 and 11,960 RSUs and 3,800 fully vested stock options into common stock, including 3,800 shares at an exercise price of $3.38. After these transactions, he directly owned 66,086 common shares, including 1,033 shares acquired under the employee stock purchase plan.
Morgan Stanley Smith Barney LLC filed a Form 144 reporting proposed sales of Common shares for Franklin M. Stokes.
The notice lists a sale of 7,000 Common shares on
CSTL submitted a Form 144 notice reporting a proposed sale of 4,748 common shares via a stock option exercise dated 03/05/2026.
Broker/dealer listed is Morgan Stanley Smith Barney LLC. The filing also lists previously issued restricted stock quantities of 830 (06/10/2022) and 1,825 (06/02/2023).
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 reporting an intended sale of 7,000 common shares originally issued as Restricted Stock Units on
The filing identifies the securities as common stock of CSTL and provides broker details and a filing date of
Castle Biosciences, Inc. files its annual report describing its 2025 operations, growth, risks and regulatory environment as a molecular diagnostics company focused on dermatology, gastroenterology, ophthalmology and atopic dermatitis.
In 2025, Castle generated $344.2 million in net revenues and delivered 105,053 clinical test reports, up from 96,071 in 2024. Dermatologic tests accounted for 60,665 reports, while TissueCypher Barrett’s esophagus testing rose sharply to 39,014 reports. The company commenced a limited launch of its non-invasive AdvanceAD‑Tx test for moderate‑to‑severe atopic dermatitis.
The report details broad Medicare and commercial coverage for key tests such as DecisionDx‑Melanoma, TissueCypher, MyPath Melanoma, DecisionDx‑UM and (until discontinued) IDgenetix, with specific ADLT-based Medicare rates. It also explains that DecisionDx‑SCC is now non‑covered under finalized Medicare LCDs, which Castle is seeking to reconsider. Extensive risk disclosures emphasize dependence on a small number of third‑party payors, historical losses, evolving FDA and LDT regulation, intellectual property protection, and complex federal and state healthcare and privacy laws.